Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HC102
- Development stage
- Unknown
- Lead developer
- HebeCell
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
HC102 is an off-the-shelf, induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor (CAR)-engineered natural killer (NK) cell therapy being developed by HebeCell. It is currently in Phase 1 clinical development for the treatment of metastatic ovarian cancer. The therapy utilizes HebeCell's proprietary 3D-PSC platform to generate large quantities of homogeneous NK cells from pluripotent stem cells, which are then engineered with a CAR to specifically target and eliminate ovarian tumor cells. By combining the innate cytotoxic capabilities of NK cells with the specificity of a CAR, HC102 aims to provide a potent, scalable, and standardized treatment option for patients with advanced ovarian malignancies, potentially overcoming the limitations associated with autologous cell therapies.
Beyond the preview
Go deeper on HC102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HC102.